Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease.

Amy Po Yu TsaiSeo Am HurAlyson WongMohsen SafaviDeborah AssayagKerri A JohannsonJulie MorissetCharlene FellJolene H FisherHélène ManganasShane ShaperaGerard CoxAndrea S GershonNathan HamblyNasreen KhalilTeresa ToPearce George WilcoxAndrew HalaykoMartin Rj KolbChristopher J Ryerson

Published in: Thorax (2020)

We used a large and diverse cohort of patients with a variety of fibrotic ILD subtypes to suggest validity and MID of both the EQ-5D-5L and EQ-VAS. These findings will assist in designing future clinical trials and supporting cost-effectiveness analyses of potential treatments for patients with fibrotic ILD.

Keyphrases

interstitial lung disease
systemic sclerosis
idiopathic pulmonary fibrosis
clinical trial
rheumatoid arthritis
randomized controlled trial
current status
study protocol
placebo controlled